Trial reportAAPS PharmSciTech2014
Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride.
Trial report in AAPS PharmSciTech, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 67 citations in OpenAlex.
- Formulation, Development, and Optimization of Fast Dissolving Tablets Containing Tapentadol Hydrochloride.Pharmaceutical nanotechnology · 2026Article
- Formulation and Evaluation of Triamcinolone Acetonide-Loaded Oral Disintegrated Film with Different PolymersTurkish journal of pharmaceutical sciences · 2024Article
- Orodispersible Films: Current Innovations and Emerging Trends.Pharmaceutics · 2023Review
- Overview about Oral Films in Mental Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Hydroxypropyl Methylcellulose Orodispersible Film Containing Desloratadine for Geriatric Use: Formulation and Evaluation.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2023Article
- Article
- Neoteric Approach of Fluoxetine Laden Orodispersible Film for Non-compliant Pediatric Patients of Selective Mutism and Obsessive-compulsive Disorder.Turkish journal of pharmaceutical sciences · 2021Article
- Formulation, characterization, optimization, andDrug delivery · 2021Article
- Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol.Pharmaceutics · 2021Article
- Synthesis and Evaluation of Thiol-Conjugated Poloxamer and Its Pharmaceutical Applications.Pharmaceutics · 2021Article
- Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Production of Itraconazole Nanocrystal-Based Polymeric Film Formulations for Immediate Drug Release.Pharmaceutics · 2020Article
- Enhanced pharmacokinetic performance of dapoxetine hydrochloride via the formulation of instantly-dissolving buccal films with acidic pH modifier and hydrophilic cyclodextrin: Factorial analysis,Journal of advanced research · 2020Article
- The Gut Microbiome and Treatment-Resistance in Schizophrenia.The Psychiatric quarterly · 2020Review
- The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.International journal of biological sciences · 2019Article
- Thiolation of arabinoxylan and its application in the fabrication of controlled release mucoadhesive oral films.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study was to develop fast dissolving oral film of the antipsychotic drug, flupentixol dihydrochloride, to enhance its bioavailability, optimize its therapeutic effect when used to treat depression with anxiety, and increase the convenience and compliance by the mentally ill, developmentally disable, elderly, and pediatric patients. Six formulae were prepared with different concentrations of water-soluble polymers vis. hydroxypropyl methylcellulose (HPMC E5) and carboxymethyl cellulose (CMC) by solvent casting technique. The prepared films were subjected to characterization for folding endurance, weight variations, thickness, disintegration time, drug release pattern, and drug content. Physical compatibility between the drug and excipients was guaranteed in the selected formulation (2% HPMC) by means of differential scanning calorimetry analysis and Fourier-transform infrared spectroscopy. This formulation revealed high stability after testing according to the International Conference on Harmonisation guidelines. In vivo studies based on single phase parallel design were carried out for the optimized formulation in healthy human volunteers. The concentration of flupentixol dihydrochloride in plasma samples was analyzed by a developed validated LC-MS/MS assay method and the pharmacokinetic parameters of the established formulation were compared with the commercially available oral tablets. Faster rate of absorption of flupentixol could be obtained from the oral film formulation and the relative bioavailability was found to be 151.06% compared to the marketed product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.